Scilex Holding Company Stock Price, News & Analysis

Scilex Holding Company (Nasdaq: SCLX), a company focused on non-opioid pain management products, has completed a significant non-dilutive transaction with an institutional investor. The company exchanged $200 million worth of Semnur Pharmaceuticals common stock (12.5 million shares at $16.00 per share) for $200 million in Bitcoin (BTC).

The transaction involves Scilex's majority-owned subsidiary Semnur Pharmaceuticals (OTC: SMNR, SMNRW), and the Bitcoin has been received in Scilex's cryptocurrency account. This represents a strategic move by Scilex to convert its equity holdings into digital assets while maintaining its focus on developing treatments for acute and chronic pain, neurodegenerative and cardiometabolic diseases.

Scilex Holding Company (Nasdaq: SCLX), a non-opioid pain management company, has entered into a non-binding, non-exclusive Memorandum of Understanding (MOU) with Biconomy.com for cryptocurrency and treasury management strategies.

The collaboration focuses on three key areas: (1) utilizing Biconomy's cryptocurrency exchange platform for trading Scilex's digital assets, potentially exceeding $1 billion per cryptocurrency, (2) developing a cryptocurrency treasury management strategy balancing security, liquidity, compliance, and yield, and (3) implementing Biconomy's technology to monetize Scilex's digital assets.

Scilex Holding Company (Nasdaq: SCLX) has announced a significant strategic transaction involving the exchange of its Semnur Pharmaceuticals stock holdings for cryptocurrency. The company has signed a Securities Purchase Agreement to exchange $200 million worth of Semnur Pharmaceuticals common stock (12.5 million shares at $16.00 per share) for $200 million in Bitcoin.

The transaction, expected to close on September 23, 2025, is being conducted as a private offering under Section 4(a)(2) of the Securities Act. Additionally, Scilex has partnered with Biconomy.com to assist with crypto currency strategies, including reserve building and treasury management. JW Capital Securities Limited is serving as the financial advisor for this transaction.

Semnur Pharmaceuticals (OTC: SMNR), a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX), has completed its previously announced business combination with Denali Capital Acquisition Corp. Following the merger, Scilex and its affiliates maintain approximately 87.5% ownership of Semnur's common stock.

The combined entity will continue operating as Semnur Pharmaceuticals, with its shares and warrants trading on the OTC Markets under symbols SMNR and SMNRW. The company focuses on developing non-opioid pain management therapeutics, with its lead candidate SP-102 currently in Phase 3 clinical development for chronic radicular pain/sciatica treatment.

Semnur Pharmaceuticals, a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX), announced that shareholders of Denali Capital Acquisition Corp have approved their previously announced business combination at an Extraordinary General Meeting held on September 3, 2025.

The combined entity will operate as Semnur Pharmaceuticals, Inc. The merger is expected to close in September 2025, subject to customary closing conditions. The business combination approval follows Denali's filing of a definitive proxy statement/prospectus with the SEC on August 13, 2025.

Scilex Holding Company is a revenue-generating company focused on non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic disease treatments.

Scilex Holding Company (Nasdaq: SCLX) announced two major developments: a $20 million private placement for its majority-owned subsidiary Semnur Pharmaceuticals, and a leadership transition. The private placement involves selling 1,250,000 shares at $16.00 per share to advance SP-102's second Phase 3 clinical trial for LRP/Sciatica treatment.

Additionally, Jaisim Shah has stepped down as Scilex's CEO and President to focus full-time on his role as CEO of Semnur, while remaining on Scilex's Board. Dr. Henry Ji, previously Executive Chairman, has been appointed as Scilex's new CEO and President. These changes come as Semnur prepares for its business combination with Denali Capital Acquisition Corp, expected to close in September 2025.

Scilex Holding Company (Nasdaq: SCLX) announced that the SEC has declared effective the Form S-4 registration statement for the proposed business combination between Denali Capital Acquisition Corp. (OTCB: DNQAF) and Semnur Pharmaceuticals, Scilex's majority-owned subsidiary.

The extraordinary general meeting for Denali shareholders is scheduled for September 3, 2025, at 9:00 AM ET in New York. Shareholders of record as of August 12, 2025, will be eligible to vote. Upon completion, the combined company will be renamed to Semnur Pharmaceuticals, Inc. While an application for Nasdaq listing has been submitted, approval remains pending.

Scilex Holding Company (Nasdaq: SCLX), a company focused on non-opioid pain management products, has announced the deferral of its previously announced dividend record date. The dividend, which consists of Scilex preferred stock exchangeable for up to 10% of Scilex's ownership interest in Semnur Pharmaceuticals, was originally scheduled for May 2, 2025.

The Board of Directors will determine a new record date at their discretion and maintains the right to further modify the date or revoke the dividend entirely. This dividend would affect both stockholders and certain other securityholders of Scilex.

Scilex Holding Company (SCLX) announced a publication highlighting GLOPERBA's dosing adjustments in a peer-reviewed journal. GLOPERBA is the first liquid oral colchicine for gout flare prophylaxis, enabling precision dosing for patients with renal impairment. The study reveals that patients with renal issues taking standard colchicine formulations often receive sub-optimal or excessive doses. The research demonstrates that GLOPERBA's liquid format allows for more precise dosing: 0.48 mg for moderate renal impairment and 0.3 mg for severe renal impairment, leading to better therapeutic outcomes. This is particularly significant as over 70% of gout patients have comorbid conditions requiring dose adjustments.